Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Christina Psaros et al.|The Lancet HIV|2023Cited by 14
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialAdeola Adeyeye, Zhe Wang, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 0